Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live

Sep 29

Ginkgo Bioworks' (DNA) Datapoints and Apheris said Tuesday that AbbVie (ABBV), argenx (ARGX), Lundbeck, and Takeda (TAK) will join them as founding members of the Antibody Developability Consortium.

The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.

The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.

The consortium is targeting an initial dataset by early 2027, they added.

Price: 11.01, Change: +0.55, Percent Change: +5.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2671142248"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2671142248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2671142248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2671142248","market":"nz","top_or_hot":-1,"title":"Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a>' (DNA) Datapoints and Apheris said Tuesday that AbbVie (ABBV), argenx (ARGX), Lundbeck, and Takeda (TAK) will join them as founding members of the Antibody Developability Consortium.</p><p>The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.</p><p>The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.</p><p>The consortium is targeting an initial dataset by early 2027, they added.</p><p>Price: 11.01, Change: +0.55, Percent Change: +5.26</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-29 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a>' (DNA) Datapoints and Apheris said Tuesday that AbbVie (ABBV), argenx (ARGX), Lundbeck, and Takeda (TAK) will join them as founding members of the Antibody Developability Consortium.</p><p>The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.</p><p>The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.</p><p>The consortium is targeting an initial dataset by early 2027, they added.</p><p>Price: 11.01, Change: +0.55, Percent Change: +5.26</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1585245621.USD","symbol_name":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2671142248","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2671142248","pubTimestamp":1790692316,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ginkgo Bioworks'  Datapoints and Apheris said Tuesday that AbbVie , argenx , Lundbeck, and Takeda  will join them as founding members of the Antibody Developability Consortium.The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.The consortium is targeting an initial dataset by early 2027, they added.Price: 11.01, Change: +0.55, Percent Change: +5.26","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AGNG":"Global X Aging Population ETF","IXJ":"全球医疗业ETF-iShares","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","IYH":"iShares U.S. Healthcare ETF","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","BK4534":"瑞士信贷持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","DNA.AU":"DONACO INTL LTD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","PPH":"VanEck Pharmaceutical ETF","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","FHLC":"Fidelity MSCI Health Care Index","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","DNA":"Ginkgo Bioworks Holdings Inc.","PJP":"INVESCO PHARMACEUTICALS ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","TAK":"武田制药","VHT":"Vanguard Health Care ETF","RXL":"ProShares Ultra Health Care","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","ABBV":"艾伯维公司","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","IBB":"生物科技指数ETF-iShares Nasdaq","FMED":"Fidelity Disruptive Medicine ETF","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","BK4007":"制药","ARGX":"Argenx SE","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","XLV":"健康照护类股ETF-SPDR","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF"},"translate_title":"Ginkgo Datapoints、Apheris、艾伯维等组成抗体开发联盟","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLAM":0.6,"FMED":0.6,"TBXU":0.6,"XLV":0.6,"RXL":0.6,"MEDX":0.6,"PJP":0.6,"FTXH":0.6,"FHLC":0.6,"AGNG":0.6,"DNA":1,"IBB":0.6,"TAK":1,"DNA.AU":1,"JDOC":0.6,"VHT":0.6,"ARGX":1,"PPH":0.6,"TRUH":0.6,"IXJ":0.6,"IYH":0.6,"ABBV":1.5},"content_text":"Ginkgo Bioworks' (DNA) Datapoints and Apheris said Tuesday that AbbVie (ABBV), argenx (ARGX), Lundbeck, and Takeda (TAK) will join them as founding members of the Antibody Developability Consortium.The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.The consortium is targeting an initial dataset by early 2027, they added.Price: 11.01, Change: +0.55, Percent Change: +5.26","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}